Intellia Therapeutics to Present at Chardan’s 5th Annual Genetic Medicines Conference
27 September 2021 - 9:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing curative therapeutics
using CRISPR/Cas9 technology both in vivo and ex vivo, will present
at Chardan’s 5th Annual Genetic Medicines Conference on Monday,
October 4, 2021 at 10:30 a.m. ET.
A live webcast of Intellia’s presentation at this event will be
accessible through the Events and Presentations page of the
Investor Relations section of the company’s website
at www.intelliatx.com. To access the webcast, please log on to
the Intellia website approximately 15 minutes prior to the start
time to ensure adequate time for any software downloads that may be
required. A replay of the webcast will be available on Intellia’s
website for approximately 14 days following the presentation.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics using
CRISPR/Cas9 technology. To fully realize the transformative
potential of CRISPR/Cas9, Intellia is pursuing two primary
approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the
therapy by using engineered human cells to treat cancer and
autoimmune diseases. Intellia’s deep scientific, technical and
clinical development experience, along with its robust intellectual
property portfolio, have enabled the company to take a leadership
role in harnessing the full potential of CRISPR/Cas9 to create new
classes of genetic medicine. Learn more at intelliatx.com.
Follow us on Twitter @intelliatweets.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024